A modified Plasmodium falciparum growth inhibition assay (GIA) to assess activity of plasma from malaria endemic areas.
Plasma samples from patients undergoing treatment in malaria endemic countries often contain anti-malaria drugs, that may overstate effects of specific antibodies in growth inhibition assays (GIA). We describe a modified assay that uses drug resistant P. falciparum parasites (W2) that circumvents the requirement for dialyzing samples that may likely contain drugs such as chloroquine and sulfadoxine/pyrimethamine (SP).
Mlambo
Godfree
G
Malaria Research Institute, Department of Microbiology and Immunology, Johns Hopkins University, Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD 21205, USA.
Kumar
Nirbhay
N
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood* / Q000276:immunology; D000962:Antimalarials / Q000097:blood / Q000494:pharmacology; D002738:Chloroquine / Q000097:blood / Q000494:pharmacology; D003956:Dialysis; D004306:Dose-Response Relationship, Immunologic; D004351:Drug Resistance; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000032:analysis; D010963:Plasmodium falciparum / Q000187:drug effects / Q000254:growth & development* / Q000276:immunology; D011739:Pyrimethamine / Q000494:pharmacology
D000913:Antibodies, Protozoan; D000962:Antimalarials; D002738:Chloroquine; D007770:L-Lactate Dehydrogenase; D011739:Pyrimethamine